<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03585465</url>
  </required_header>
  <id_info>
    <org_study_id>Metro-PD1-1708</org_study_id>
    <nct_id>NCT03585465</nct_id>
  </id_info>
  <brief_title>Nivolumab in Combination With Metronomic Chemotherapy in Paediatrics Refractory / Relapsing Solid Tumors</brief_title>
  <official_title>Metro-PD1: a Phase I/II Trial Evaluating Anti-PD1 (Nivolumab) in Combination With Metronomic Chemotherapy in Children and Teenagers With Refractory / Relapsing Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Oscar Lambret</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Anticancer Fund, Belgium</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>CTD-CNO</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Centre Oscar Lambret</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study is a two-stage trial:&#xD;
&#xD;
        1. First stage (closed - 16 patients recruited in France):&#xD;
&#xD;
           Phase I feasibility trial to evaluate the safety of the combination of Nivolumab +&#xD;
           metronomic chemotherapy considering three possible metronomic chemotherapy regimens&#xD;
&#xD;
        2. Second stage (opened - 86 patients expected in France and Belgium):&#xD;
&#xD;
      Phase II randomized controlled balanced 1:1 open-label trial comparing the efficacy of the&#xD;
      metronomic chemotherapy regimen selected at the end of the previous stage (arm C:&#xD;
      cyclophosphamide, capecitabine, vinblastine), with or without nivolumab.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      1. First stage (closed):&#xD;
&#xD;
             -  Arm A: Nivolumab + Cyclophosphamide-Vinblastine&#xD;
&#xD;
             -  Arm B: Nivolumab + Capecitabin&#xD;
&#xD;
             -  Arm C: Nivolumab + Cyclophosphamide-Vinblastine + Capecitabin&#xD;
&#xD;
           Arm A and Arm B have been allocated sequentially (A/B/A/B/A/B). Arm C has been opened,&#xD;
           since arm A and Arm B were deemed safe.&#xD;
&#xD;
           In each arm, the second patient was not recruited before the first patient has been&#xD;
           observed for a 28-day duration.&#xD;
&#xD;
        2. Second stage (opened):&#xD;
&#xD;
      Following the analysis of safety data from first stage, and according to IDMC's&#xD;
      recommendations on December 2020, the metronomic chemotherapy selected for second stage was&#xD;
      arm C: cyclophosphamide, capecitabine, vinblastine&#xD;
&#xD;
      Randomization will be balanced 1:1, controlling for:&#xD;
&#xD;
        -  histological type: embryonal brain tumor, ependymoma, low-grade glioma,&#xD;
           rhabdomyosarcoma, neuroblastoma, Ewing sarcoma, and other solid tumors after approval&#xD;
           from coordinators,&#xD;
&#xD;
        -  and treating center, using a dynamic allocation of treatment (minimization program) with&#xD;
           a random factor set at 0.8.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 26, 2019</start_date>
  <completion_date type="Anticipated">January 2028</completion_date>
  <primary_completion_date type="Anticipated">May 2025</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Dose Limiting Toxicities according to the NCI-CTCAE V5</measure>
    <time_frame>Over the first chemotherapy cycle (28 days)</time_frame>
    <description>First Stage Primary Outcome 3 metronomic CT are : A:Cyclophosphamide + Vinblastine B:Capecitabin C:Cyclophosphamide + Vinblastine + Capecitabin</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Progression-free survival according appropriate criteria (RANO, RAPNO, WHO, INRC, RECIST v1.1).</measure>
    <time_frame>up to 2 years</time_frame>
    <description>Second Stage Primary Outcome Metronomic chemotherapy is the same as regimen selected at the end of the first stage</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adverse events according to the NCI-CTCAE V5.</measure>
    <time_frame>up to 2 years</time_frame>
    <description>First Stage Secondary Outcome 1 &amp; Second Stage Secondary Outcome 1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tumor response in terms of complete/partial response or stable/progressive disease (using RANO, RAPNO, WHO, INRC, or RECIST v1.1) and overall survival</measure>
    <time_frame>up to 2 years</time_frame>
    <description>Second Stage Secondary Outcome 2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dose-intensity for each drug (ratio between the computed dose-intensity, and the protocol dose-intensity)</measure>
    <time_frame>up to 2 years</time_frame>
    <description>First Stage Secondary Outcome 2 &amp; Second Stage Secondary Outcome 3</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Anticipated">102</enrollment>
  <condition>Childhood Solid Tumor</condition>
  <arm_group>
    <arm_group_label>A: Cyclophosphamide Vinblastine Nivolumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>This arm was applicable to first stage, and is closed</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B: Capecitabine Nivolumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>This arm was applicable to first stage, and is closed</description>
  </arm_group>
  <arm_group>
    <arm_group_label>C: Cyclophosphamide Vinblastine Capecitabine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>This arm was applicable to first stage, and is closed</description>
  </arm_group>
  <arm_group>
    <arm_group_label>&quot;Metronomic CT &quot;</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>metronomic chemotherapy selected at the end of first stage (C: Cyclophosphamide Vinblastine Capecitabine)&#xD;
This arm is applicable to second stage, and 43 patients are expected</description>
  </arm_group>
  <arm_group>
    <arm_group_label>&quot;Metronomic CT + Nivolumab&quot;</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>metronomic chemotherapy selected at the end of first stage (C: Cyclophosphamide Vinblastine Capecitabine) + Nivolumab&#xD;
This arm is applicable to second stage, and 43 patients are expected</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vinblastine</intervention_name>
    <description>Experimentals Arm A or C (First stage): 2 mg/m2/day IV, weekly per cycle, 28 days cycle&#xD;
Experimental Arms Metronomic or Metronomic+Nivolumab (second stage): see C</description>
    <arm_group_label>&quot;Metronomic CT &quot;</arm_group_label>
    <arm_group_label>&quot;Metronomic CT + Nivolumab&quot;</arm_group_label>
    <arm_group_label>A: Cyclophosphamide Vinblastine Nivolumab</arm_group_label>
    <arm_group_label>C: Cyclophosphamide Vinblastine Capecitabine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclophosphamide</intervention_name>
    <description>Arm A (First stage): 30 mg/m2/day PO, D1-4// D8-11// D15-18// D22-25 per cycle, 28 days cycle&#xD;
Arm C (First stage): 30 mg/m2/day PO, D1-D4// D15-D18 per cycle, 28 days cycle&#xD;
Metronomic or Metronomic+Nivolumab Arm (second stage): see C</description>
    <arm_group_label>&quot;Metronomic CT &quot;</arm_group_label>
    <arm_group_label>&quot;Metronomic CT + Nivolumab&quot;</arm_group_label>
    <arm_group_label>A: Cyclophosphamide Vinblastine Nivolumab</arm_group_label>
    <arm_group_label>C: Cyclophosphamide Vinblastine Capecitabine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Capecitabine</intervention_name>
    <description>Arm B (First stage): 400 to 600 mg/m2/day PO, all days per cycle, 28 days cycle&#xD;
Arm C (First stage): 400 to 600 mg/m2/day PO, D8-D11// D22-D25 per cycle, 28 days cycle&#xD;
Metronomic or Metronomic+Nivolumab Arm (second stage): see C</description>
    <arm_group_label>&quot;Metronomic CT &quot;</arm_group_label>
    <arm_group_label>&quot;Metronomic CT + Nivolumab&quot;</arm_group_label>
    <arm_group_label>B: Capecitabine Nivolumab</arm_group_label>
    <arm_group_label>C: Cyclophosphamide Vinblastine Capecitabine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nivolumab</intervention_name>
    <description>Arm A, B or C (First stage): 3 mg/kg IV, D1 &amp; D15 per cycle, 28 days cycle&#xD;
Metronomic+Nivolumab Arm (second stage): 3 mg/kg IV, D1 &amp; D15 per cycle, 28 days cycle</description>
    <arm_group_label>&quot;Metronomic CT + Nivolumab&quot;</arm_group_label>
    <arm_group_label>A: Cyclophosphamide Vinblastine Nivolumab</arm_group_label>
    <arm_group_label>B: Capecitabine Nivolumab</arm_group_label>
    <arm_group_label>C: Cyclophosphamide Vinblastine Capecitabine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        INCLUSION CRITERIA:&#xD;
&#xD;
          -  Histologically proven diagnosis of solid malignant tumor. Confirmed progressive or&#xD;
             refractory disease despite standard therapy or for which no effective standard therapy&#xD;
             exists (this criterion is applicable to stage 1 only)&#xD;
&#xD;
          -  Histologically proven diagnosis of: embryonal brain tumor, ependymoma, low-grade&#xD;
             glioma (LGG), rhabdomyosarcoma, neuroblastoma, Ewing sarcoma, and other solid tumors&#xD;
             and after approval from coordinators (except high grade glioma, osteosarcoma,&#xD;
             lymphoma), and confirmed progressive or refractory disease despite standard therapy or&#xD;
             for which no effective standard therapy exists (this criterion is applicable to stage&#xD;
             2 only)&#xD;
&#xD;
          -  Male and female subjects &gt; 4 to &lt; 18 years of age at inclusion; patients 18 years and&#xD;
             older may be included after discussion with the sponsor if they had a pediatric&#xD;
             recurrent/refractory malignancy diagnosed before the age of 18.&#xD;
&#xD;
          -  Evaluable or measurable disease as defined by adequate standard imaging criteria for&#xD;
             each patient's tumor type (see corresponding appendices for definition of evaluable&#xD;
             and/or measurable lesions):&#xD;
&#xD;
               -  RANO criteria for patients with high grade glioma (HGG), who are eligible at&#xD;
                  stage 1 only&#xD;
&#xD;
               -  RAPNO criteria for patients with low grade glioma&#xD;
&#xD;
               -  WHO for other cerebral tumors&#xD;
&#xD;
               -  INRC criteria for patients with neuroblastoma (NB),&#xD;
&#xD;
               -  RECIST v1.1 for tumors other than cerebral tumors and neuroblastoma&#xD;
&#xD;
          -  Performance status: Karnofsky performance status (for patients &gt;12 years of age) or&#xD;
             Lansky Play score (for patients ≤12 years of age) ≥ 70%.&#xD;
&#xD;
        Patients who are unable to walk because of paralysis or stable neurological disability, but&#xD;
        who are up in a wheelchair, will be considered ambulatory for the purpose of assessing the&#xD;
        performance score.&#xD;
&#xD;
          -  Life expectancy ≥ 3 months&#xD;
&#xD;
          -  Adequate organ function:&#xD;
&#xD;
          -  Hematologic criteria - Peripheral absolute neutrophil count (ANC) ≥ 1500/mm3&#xD;
             (unsupported)&#xD;
&#xD;
          -  White blood cells count ≥ 2500/mm3&#xD;
&#xD;
          -  Platelet count ≥ 100,000/mm3 (unsupported)&#xD;
&#xD;
          -  Hemoglobin ≥ 8.0 g/dL (transfusion is allowed)&#xD;
&#xD;
          -  Cardiac function - Shortening fraction (SF) &gt;29% (&gt;35% for children &lt; 3 years) and&#xD;
             left ventricular ejection fraction (LVEF) ≥50% at baseline, as determined by&#xD;
             echocardiography (mandatory only for patients who have received cardiotoxic therapy).&#xD;
             - Absence of QTc prolongation (QTc &gt; 450 msec on baseline ECG, using the Fridericia&#xD;
             correction [QTcF formula]) or other clinically significant ventricular or atrial&#xD;
             arrhythmia.&#xD;
&#xD;
          -  Renal and hepatic function - Serum creatinine &lt; 1.5 x upper limit of normal (ULN) for&#xD;
             age&#xD;
&#xD;
          -  Total bilirubin &lt; 1.5 x ULN,&#xD;
&#xD;
          -  Alanine aminotransferase (ALT)/serum glutamic pyruvic transaminase (SGPT) &lt; 3 x ULN;&#xD;
&#xD;
          -  aspartate aminotransferase (AST)/serum glutamic oxaloacetic transaminase/SGOT &lt; 3 x&#xD;
             ULN&#xD;
&#xD;
          -  Able to comply with scheduled follow-up and with management of toxicity.&#xD;
&#xD;
          -  Females of child bearing potential must have a negative serum or urine pregnancy test&#xD;
             within 7 days prior to initiation of treatment.&#xD;
&#xD;
          -  Sexually active patients must agree to use adequate and appropriate contraception&#xD;
             while on study drug and for 6 months after stopping the study drug.&#xD;
&#xD;
          -  Patient able to comfortably swallow capsules.&#xD;
&#xD;
          -  Patients on stable doses of corticosteroids (≤0.25 mg/kg prednisolone or equivalent)&#xD;
             for at least 7 days prior to receiving study drug may be included.&#xD;
&#xD;
          -  Written informed consent from parents/legal representative, patient, and&#xD;
             age-appropriate assent before any study-specific screening procedures are conducted&#xD;
             according to local, regional or national guidelines.&#xD;
&#xD;
          -  Patient affiliated to a social security regimen or beneficiary of the same according&#xD;
             to local requirements.&#xD;
&#xD;
          -  Patients can have received prior treatment with antiPD1 or antiPDL1 if at least SD for&#xD;
             6 months or PR or CR was obtained.&#xD;
&#xD;
        EXCLUSION CRITERIA:&#xD;
&#xD;
          -  Leukemia&#xD;
&#xD;
          -  Diagnosis of lymphoma, high grade glioma (HGG) including diffuse intrinsic pontine&#xD;
             glioma or osteosarcoma (for stage 2 only)&#xD;
&#xD;
          -  Patients with symptomatic central nervous system (CNS) metastases who are&#xD;
             neurologically unstable or require increasing doses of corticosteroids or local&#xD;
             CNS-directed therapy to control their CNS disease.&#xD;
&#xD;
          -  Patients requiring high doses of corticosteroids &gt;0.25mg/kg prednisolone or&#xD;
             equivalent) or increasing doses of corticosteroids during the 7 days prior to&#xD;
             receiving study drug.&#xD;
&#xD;
          -  For patients with CNS tumor:&#xD;
&#xD;
             o Evidence of &gt; Grade 1 recent CNS hemorrhage on the baseline MRI scan.&#xD;
&#xD;
             o Participants with bulky tumor on imaging are ineligible; bulky tumor is defined as:&#xD;
             i) Tumor with any evidence of uncal herniation or severe midline shift ii) Tumor with&#xD;
             diameter of &gt; 6 cm in one dimension on contrast-enhanced MRI iii) Tumor that in the&#xD;
             opinion of the investigator, shows significant mass effect&#xD;
&#xD;
          -  Impairment of gastrointestinal (GI) function or GI disease that may significantly&#xD;
             alter drug absorption of oral drugs (e.g., ulcerative diseases, uncontrolled nausea,&#xD;
             vomiting, diarrhea, or malabsorption syndrome).&#xD;
&#xD;
          -  Clinically significant, uncontrolled heart disease (including history of any cardiac&#xD;
             arrhythmias, e.g., ventricular, supraventricular, nodal arrhythmias, or conduction&#xD;
             abnormality within 12 months of screening)&#xD;
&#xD;
          -  Active viral hepatitis or known human immunodeficiency virus (HIV) infection or any&#xD;
             other uncontrolled infection.&#xD;
&#xD;
          -  Active autoimmune disease requiring immunosuppressive treatment&#xD;
&#xD;
          -  Known congenital immunodeficiency&#xD;
&#xD;
          -  Presence of any NCI-CTCAE v5 grade ≥ 2 treatment-related extra-hematological toxicity&#xD;
             with the exception of alopecia, ototoxicity or peripheral neuropathy.&#xD;
&#xD;
          -  Systemic anticancer therapy within 21 days of the first study dose or 5 times its&#xD;
             half-life, whichever is less, 6 weeks in case of nitrosourea.&#xD;
&#xD;
          -  No clinical benefit with previous antiPD1 or antiPDL1 treatment (SD during a period&#xD;
             inferior to 6 months, or PD).&#xD;
&#xD;
          -  Previous myeloablative therapy with autologous hematopoietic stem cell rescue within 8&#xD;
             weeks of the first study drug dose.&#xD;
&#xD;
          -  Allogeneic stem cell transplant within 3 months prior to the first study drug dose.&#xD;
             Patients receiving any agent to treat or prevent graft-versus host disease (GVHD) post&#xD;
             bone marrow transplant are not eligible for this trial.&#xD;
&#xD;
          -  Radiotherapy (non-palliative) within 21 days prior to the first dose of drug (or&#xD;
             within 6 weeks for therapeutic doses of MIBG or craniospinal irradiation).&#xD;
&#xD;
          -  Major surgery within 21 days of the first dose. Gastrostomy, ventriculo-peritoneal&#xD;
             shunt, endoscopic ventriculostomy, tumor biopsy and insertion of central venous access&#xD;
             devices are not considered major surgery, but for these procedures, a 48 hour interval&#xD;
             must be maintained before the first dose of the investigational drug is administered.&#xD;
&#xD;
          -  Currently taking medications with a known risk of prolonging the QT interval or&#xD;
             inducing Torsades de Pointes.&#xD;
&#xD;
          -  Known hypersensitivity to any study drug or component of the formulation.&#xD;
&#xD;
          -  Absence of effective contraception in patients of childbearing age&#xD;
&#xD;
          -  Pregnant or nursing (lactating) females.&#xD;
&#xD;
          -  Vaccination with live, attenuated vaccines within 4 weeks of the first dose of the&#xD;
             study drugs except inactivated vaccines.&#xD;
&#xD;
          -  Known absence of dihydro-pyrimidine-deshydrogenase (DPD) activity; although a DPD&#xD;
             deficiency can't be precisely defined, it is known that patients carrying some&#xD;
             homozygous or heterozygous mutations of DPYD responsible for the complete or almost&#xD;
             complete absence of enzymatic activity of DPD, are exposed to a maximum risk of&#xD;
             life-threatening or fatal toxicity and should not be treated with capecitabine&#xD;
&#xD;
          -  Patients with galactose intolerance, Lapp lactase deficiency or glucose or galactose&#xD;
             malabsorption syndrome (rare hereditary diseases)&#xD;
&#xD;
          -  Acute urinary tract infection, pre-existing hemorrhagic cystitis; obstruction of the&#xD;
             urinary tract&#xD;
&#xD;
          -  History of organ transplant&#xD;
&#xD;
          -  Severe infections requiring parenteral antibiotic therapy&#xD;
&#xD;
          -  Active tuberculosis&#xD;
&#xD;
          -  History of interstitial lung disease&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>4 Years</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pierre LEBLOND, MD</last_name>
    <role>Study Director</role>
    <affiliation>Centre Oscar Lambret</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Nicolas ANDRE, MD</last_name>
    <role>Study Director</role>
    <affiliation>CHU La Timone</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Leen WILLEMS, MD</last_name>
    <role>Study Director</role>
    <affiliation>University Hospital, Ghent</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Alicia PROBST</last_name>
    <phone>+33320295918</phone>
    <email>promotion@o-lambret.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Cliniques Universitaires Saint-Luc (CUSL)</name>
      <address>
        <city>Brussel</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>University Hospital Ghent</name>
      <address>
        <city>Gent</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>University Hospital Leuven</name>
      <address>
        <city>Leuven</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Centre Oscar Lambret</name>
      <address>
        <city>Lille</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anne-Sophie DEFACHELLES</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Léon Bérard (IHOPe)</name>
      <address>
        <city>Lyon</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pierre LEBLOND</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hôpital La Timone, AP-HM</name>
      <address>
        <city>Marseille</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nicolas ANDRE</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hôpital d'Enfants - CHRU Nancy</name>
      <address>
        <city>Nancy</city>
        <country>France</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hôpital Mère-Enfant, CHU Nantes</name>
      <address>
        <city>Nantes</city>
        <country>France</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Institut Curie</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Isabelle AERTS</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hôpital de Hautepierre, CHRU Strasbourg</name>
      <address>
        <city>Strasbourg</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Natacha ENTZ-WERLE</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hôpital des Enfants - CHU Toulouse</name>
      <address>
        <city>Toulouse</city>
        <country>France</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>France</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>June 14, 2018</study_first_submitted>
  <study_first_submitted_qc>July 11, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">July 13, 2018</study_first_posted>
  <last_update_submitted>May 7, 2021</last_update_submitted>
  <last_update_submitted_qc>May 7, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 11, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Capecitabine</mesh_term>
    <mesh_term>Nivolumab</mesh_term>
    <mesh_term>Vinblastine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

